Treatment of liver metastases from colorectal cancer: What is the best approach today?

G. Biasco, E. Gallerani

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Liver is the common site for metastases from colorectal cancer. The 5-year overall survival rate of patients following radical operations is 25%. Surgery can be carried out in only 10-15% of the patients, yet it remains the potential curative treatment for resectable lesions. For the unresectable cancers, only chemotherapy is recommended. New drugs such as Irinotecan prolongs the overall survival of patients affected by advanced disease. In patients with unresectable metastases at diagnosis, pre-surgical treatment with Oxaliplatin leads to reduction of the lesions, allowing resection in 16% of cases. Chemotherapy may be delivered directly into the liver via the hepatic artery. No, clinical trials, to date, have shown convincing survival results in patients treated with this procedure. Combined hepatic artery and systemic treatment may provide a new strategy as adjuvant therapy for patients undergoing resections.

Original languageEnglish
Pages (from-to)438-444
Number of pages7
JournalDigestive and Liver Disease
Volume33
Issue number5
Publication statusPublished - 2001

Fingerprint

Colorectal Neoplasms
Neoplasm Metastasis
Liver
oxaliplatin
irinotecan
Hepatic Artery
Therapeutics
Drug Therapy
Survival
Survival Rate
Clinical Trials
Pharmaceutical Preparations
Neoplasms

Keywords

  • Colorectal cancer
  • Liver metastases
  • Local chemotherapy
  • Systemic chemotherapy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Treatment of liver metastases from colorectal cancer : What is the best approach today? / Biasco, G.; Gallerani, E.

In: Digestive and Liver Disease, Vol. 33, No. 5, 2001, p. 438-444.

Research output: Contribution to journalArticle

@article{12c4793eb20a41caabcb2e55f09d2aaf,
title = "Treatment of liver metastases from colorectal cancer: What is the best approach today?",
abstract = "Liver is the common site for metastases from colorectal cancer. The 5-year overall survival rate of patients following radical operations is 25{\%}. Surgery can be carried out in only 10-15{\%} of the patients, yet it remains the potential curative treatment for resectable lesions. For the unresectable cancers, only chemotherapy is recommended. New drugs such as Irinotecan prolongs the overall survival of patients affected by advanced disease. In patients with unresectable metastases at diagnosis, pre-surgical treatment with Oxaliplatin leads to reduction of the lesions, allowing resection in 16{\%} of cases. Chemotherapy may be delivered directly into the liver via the hepatic artery. No, clinical trials, to date, have shown convincing survival results in patients treated with this procedure. Combined hepatic artery and systemic treatment may provide a new strategy as adjuvant therapy for patients undergoing resections.",
keywords = "Colorectal cancer, Liver metastases, Local chemotherapy, Systemic chemotherapy",
author = "G. Biasco and E. Gallerani",
year = "2001",
language = "English",
volume = "33",
pages = "438--444",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "5",

}

TY - JOUR

T1 - Treatment of liver metastases from colorectal cancer

T2 - What is the best approach today?

AU - Biasco, G.

AU - Gallerani, E.

PY - 2001

Y1 - 2001

N2 - Liver is the common site for metastases from colorectal cancer. The 5-year overall survival rate of patients following radical operations is 25%. Surgery can be carried out in only 10-15% of the patients, yet it remains the potential curative treatment for resectable lesions. For the unresectable cancers, only chemotherapy is recommended. New drugs such as Irinotecan prolongs the overall survival of patients affected by advanced disease. In patients with unresectable metastases at diagnosis, pre-surgical treatment with Oxaliplatin leads to reduction of the lesions, allowing resection in 16% of cases. Chemotherapy may be delivered directly into the liver via the hepatic artery. No, clinical trials, to date, have shown convincing survival results in patients treated with this procedure. Combined hepatic artery and systemic treatment may provide a new strategy as adjuvant therapy for patients undergoing resections.

AB - Liver is the common site for metastases from colorectal cancer. The 5-year overall survival rate of patients following radical operations is 25%. Surgery can be carried out in only 10-15% of the patients, yet it remains the potential curative treatment for resectable lesions. For the unresectable cancers, only chemotherapy is recommended. New drugs such as Irinotecan prolongs the overall survival of patients affected by advanced disease. In patients with unresectable metastases at diagnosis, pre-surgical treatment with Oxaliplatin leads to reduction of the lesions, allowing resection in 16% of cases. Chemotherapy may be delivered directly into the liver via the hepatic artery. No, clinical trials, to date, have shown convincing survival results in patients treated with this procedure. Combined hepatic artery and systemic treatment may provide a new strategy as adjuvant therapy for patients undergoing resections.

KW - Colorectal cancer

KW - Liver metastases

KW - Local chemotherapy

KW - Systemic chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0034912691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034912691&partnerID=8YFLogxK

M3 - Article

C2 - 11529658

AN - SCOPUS:0034912691

VL - 33

SP - 438

EP - 444

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 5

ER -